Drug intelligence / Profile preview

RC220

Development stage: Phase 1
Lead developer: Race Oncology
Modality: Small Molecules
Administration: Intravenous

Overview

RC220 is a proprietary formulation of bisantrene developed by Race Oncology. It has been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of acute myeloid leukemia (AML). The drug is currently in clinical development for both AML and advanced solid tumors. RC220 represents an improved formulation of bisantrene that has eliminated phlebitis, a previous barrier to clinical use. Preclinical evidence suggests RC220 may have dual functionality - treating cancer while also providing cardioprotective effects, particularly when used alongside cardiotoxic chemotherapies like doxorubicin.

Targets

DNA

Beyond the preview

Go deeper on RC220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC220.

Explore the full profile